Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA
Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )
17 Dec 2024

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany
Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )
17 Dec 2024

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
17 Dec 2024

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL

Dr Rachel Rau - University of Washington, Seattle, USA
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )
16 Dec 2024

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Beat AML master trial update: A clinical trial for acute myeloid leukaemia

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Beat AML master trial update: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
16 Dec 2024

Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC

Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece
Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC ( Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece )
13 Dec 2024

Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients

Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy
Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients ( Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy )
13 Dec 2024

Special Issue: Palliative care in cancer – creativity and innovation in action

Dr Fiona Rawlinson - Cardiff University School of Medicine, Cardiff, UK
Special Issue: Palliative care in cancer – creativity and innovation in action ( Dr Fiona Rawlinson - Cardiff University School of Medicine, Cardiff, UK )
9 Dec 2024